Claims
- 1. A crystalline form of S-[2-[(1-Iminoethyl)amino]ethyl]-2-methyl-L-cysteine maleate characterized by at least one of: melting point of about 77.69° C.; x-ray powder pattern substantially as shown in FIG. 15; x-ray powder pattern substantially as shown in FIG. 16; unit cell as shown in FIG. 14; and elemental analysis substantially as in Table 7.
- 2. A pharmaceutical composition comprising the crystalline S-[2-[(1-Iminoethyl)amino]ethyl]-2-methyl-L-cysteine maleate Form II of claim 1 together with a pharmaceutically acceptable carrier.
- 3. A method of treating a condition wherein pathologically high production forms a part in a subject in need of such treatment comprising administering to the subject an effective amount of the crystalline S-[2-[(1-Iminoethyl)amino]ethyl]-2-methyl-L-cysteine maleate Form II of claim 1.
- 4. A method of decreasing nitric oxide production in a subject comprising administering to the subject an effective amount of the crystalline S-[2-[(1-Iminoethyl)amino]ethyl]-2-methyl-L-cysteine maleate Form II of claim 1.
Parent Case Info
[0001] Priority is claimed from U.S. Provisional Application Serial No. 60/453,782, filed Mar. 11, 2003 incorporated herein by reference
Provisional Applications (1)
|
Number |
Date |
Country |
|
60453782 |
Mar 2003 |
US |